Stock Events

Stock Events

ARS Pharmaceuticals 

$5.62
55
-$0.05-0.88% Friday 19:59
-$0.02-0.36%Friday 23:53After hours

Statistics

Day High
5.62
Day Low
5.61
52W High
13.15
52W Low
4.91
Volume
24,662
Avg. Volume
-
Mkt Cap
558.89M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.63
-0.26
0.11
0.48
Expected EPS
-0.285
Actual EPS
N/A

Financials

-203.25%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
84.28MRevenue
-171.3MNet Income

Analyst Ratings

27.00Average Price Target
The highest estimate is 30.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SPRY. It's not an investment recommendation.
NVIDIA
15
NVDA
Alphabet
12
GOOGL
Amazon
11
AMZN
Apple
10
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical is a global leader in generic and specialty medicines, including treatments for respiratory conditions, making it a direct competitor in the pharmaceutical market.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is involved in the development of respiratory treatments among its diverse pharmaceutical portfolio, competing in the same therapeutic area as ARS.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline has a significant presence in the respiratory treatment market, including asthma and COPD, directly competing with ARS Pharmaceuticals.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. offers a wide range of health solutions, including respiratory disease treatments, making it a competitor in the pharmaceutical industry.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad portfolio that includes respiratory drugs, competing with ARS Pharmaceuticals in the development and marketing of these treatments.
Novartis
NVS
Mkt Cap292.35B
Novartis AG, with its extensive research and development in respiratory conditions, competes in the same market as ARS Pharmaceuticals.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, known for its innovative biopharmaceuticals, competes in the development of treatments for conditions that ARS Pharmaceuticals targets.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is focused on serious diseases, including cystic fibrosis, a respiratory condition, making it a competitor.
Sanofi
SNY
Mkt Cap107.39B
Sanofi focuses on global healthcare and provides treatments for respiratory conditions, competing with ARS Pharmaceuticals in the same therapeutic area.

About

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
Show more...
CEO
Donn Casale
Employees
200
Country
United States
ISIN
US82835W1080

Listings

XNAS
US
SPRY
BOATS
BOATS
SPRY.BOATS

0 Comments

Share your thoughts

FAQ

What is ARS Pharmaceuticals stock price today?▼
The current price of SPRY is $5.62 USD — it has decreased by -0.88% in the past 24 hours. Watch ARS Pharmaceuticals stock price performance more closely on the chart.
What is ARS Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange ARS Pharmaceuticals stocks are traded under the ticker SPRY.
Is ARS Pharmaceuticals stock price growing?▼
SPRY stock has fallen by -4.58% compared to the previous week, the month change is a +4.85% rise, over the last year ARS Pharmaceuticals has showed a -44.19% decrease.
What is ARS Pharmaceuticals market cap?▼
Today ARS Pharmaceuticals has the market capitalization of 558.89M
When is the next ARS Pharmaceuticals earnings date?▼
ARS Pharmaceuticals is going to release the next earnings report on November 17, 2026.
What were ARS Pharmaceuticals earnings last quarter?▼
SPRY earnings for the last quarter are -0.63 USD per share, whereas the estimation was -0.48 USD resulting in a -31.89% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is ARS Pharmaceuticals revenue for the last year?▼
ARS Pharmaceuticals revenue for the last year amounts to 84.28M USD.
What is ARS Pharmaceuticals net income for the last year?▼
SPRY net income for the last year is -171.3M USD.
How many employees does ARS Pharmaceuticals have?▼
As of September 05, 2026, the company has 200 employees.
In which sector is ARS Pharmaceuticals located?▼
ARS Pharmaceuticals operates in the Health & Wellness sector.
When did ARS Pharmaceuticals complete a stock split?▼
ARS Pharmaceuticals has not had any recent stock splits.
Where is ARS Pharmaceuticals headquartered?▼
ARS Pharmaceuticals is headquartered in SAN DIEGO, United States.